Effects of calmodulin antagonists and anesthetics on the skin lesions induced by 2-chloroethylethyl sulfide.
The effects of calmodulin antagonists and anesthetics on the skin lesions induced by an alkylating vesicant, 2-chloroethylethyl sulfide, were investigated using female hairless mice. 2-Chloroethylethyl sulfide, topically applied (0.6 microliter/5 mm in diameter) on the back skin of hairless mice, induced mild to moderate petechiae on the 1st day, and ulcers with a thick scab after 3 days. The healing process started after 6 days, resulting in shedding of scabs on 9.52 days. Water-soluble ointment bases showed some beneficial effects, whereas oily bases made the skin lesions worse. Trifluoperazine (0.5-1%) and thioridazine (2%), potent calmodulin antagonists, in Pluronic F-127 base substantially prevented the development of 2-chloroethylethyl sulfide-induced skin lesions. A similar effect was achieved with pentamidine (10%), another type of calmodulin antagonist, but not with ketoconazole, a weak calmodulin antagonist. In addition, anesthetics, such as lidocaine and pentobarbital, showed some protection, although at high concentrations (> 5%). As judged by the microscopic appearance, trifluoperazine successfully reduced the hemorrhage and the infiltration of inflammatory cells in early skin lesions, and the formation of thick scabs, which leads to granulomatous scar tissue in late lesions. These results suggest that some calmodulin antagonists and anesthetics in water-soluble bases might be a choice for the treatment of 2-chloroethylethyl sulfide-induced skin burns.
Kim
Y B
YB
Biomedical Assessment Laboratory (1-4-4), Agency for Defense Development, Taejon, South Korea.
Hur
G H
GH
Choi
D S
DS
Shin
S
S
Han
B G
BG
Lee
Y S
YS
Sok
D E
DE
D000759:Adjuvants, Anesthesia / Q000494:pharmacology; D000287:Administration, Topical; D000779:Anesthetics, Local / Q000494:pharmacology; D000818:Animals; D002057:Burns, Chemical / Q000188:drug therapy* / Q000473:pathology; D002147:Calmodulin / Q000037:antagonists & inhibitors*; D018492:Dopamine Antagonists / Q000494:pharmacology*; D004304:Dosage Forms; D005260:Female; D008012:Lidocaine / Q000494:pharmacology; D051379:Mice; D008812:Mice, Hairless; D009151:Mustard Gas / Q000031:analogs & derivatives; D010419:Pentamidine / Q000494:pharmacology; D010424:Pentobarbital / Q000494:pharmacology; D012867:Skin / Q000378:metabolism; D013881:Thioridazine / Q000494:pharmacology*; D014268:Trifluoperazine / Q000494:pharmacology*
D000759:Adjuvants, Anesthesia; D000779:Anesthetics, Local; D002147:Calmodulin; D018492:Dopamine Antagonists; D004304:Dosage Forms; D014268:Trifluoperazine; D010419:Pentamidine; D008012:Lidocaine; D010424:Pentobarbital; D013881:Thioridazine; D009151:Mustard Gas